# EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

> **NCT01008475** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 232 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** EMD 525797 250 mg
- **DRUG:** EMD 525797 500 mg
- **DRUG:** EMD 525797 750 mg
- **DRUG:** EMD 525797 1000 mg
- **DRUG:** Cetuximab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01008475
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2016-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01008475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01008475, "EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01008475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*